{"analyses":[{"ciLowerLimit":"0.532","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.303","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.4209","paramType":"Hazard Ratio (HR)","paramValue":"0.832","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"There were not enough events/deaths to compute a median or 95% confidence interval.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"There were not enough events/deaths to compute a median or 95% confidence interval.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death from any cause. For each participant who was not known to have died as of the data-inclusion cutoff date for a particular analysis,OS was censored for that analysis at the date of last contact prior to the data-inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, lesion assessment date, visit date, and last known alive date).","dispersionType":"95% Confidence Interval","groups":[{"description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Part B: Ramucirumab+ Erlotinib"},{"description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Part B: Placebo+ Erlotinib"}],"paramType":"MEDIAN","populationDescription":"Part B: All randomized participants grouped according to their assigned treatment at randomization. Censored participants were: Part B: Ramucirumab+ Erlotinib= 187 and Part B: Placebo+ Erlotinib= 183. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","timeFrame":"Randomization to Date of Death from Any Cause (Up To 37 Months)","title":"Part B: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}